CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
orlistatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00461799
NCT00461799N/ACompleted
CompareCT.gov

Orlistat Treatment of Unconjugated Hyperbilirubinemia in Crigler-Najjar Disease; A Randomized Controlled Trial

University Medical Center Groningen·interventional·Posted Apr 18, 2007·Updated Apr 18, 2007

In Brief

A clinical study evaluating orlistat for Crigler-Najjar Syndrome. Completed, across 1 site.

Detailed Summary

The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrigler-Najjar Syndrome
CountriesNetherlands
CollaboratorsErasmus Medical Center, De Najjar Stichting

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2007
Enrollment StartSep 1, 2003
Study CompletionJan 1, 2004
TodayJul 2, 2026
Posted 19.2 years ago

Interventions

orlistatdrug